

TOPICS of interest for 2020

- PDX models: PARPi resistance in prostate and pancreas, EGFR, CDK4/6i, and ER targeted agents
- Identification of driver oncogenic & immune pathways and effects of pharmacological modulation in preclinical models, particularly explants, representative of Asian cancers
- Models of hematological malignancies(lymphoma) and EGFR and KRAS mutant lung cancer
- Best combinations with radiation in different tumor types, better tolerated DDR combinations
- Translational science studies using CT-DNA
- Understanding key metabolic pathways and dependencies in Asian cancers* (HCC, GC would be of particular interest)
- HER2 biologies
- New epigenetic targets combining with AZ compounds, and disruptive technologies

